Cargando…
Ramipril-associated cholestasis in the setting of recurrent drug-induced liver injury
Aim: Angiotensin-converting enzyme inhibitors (ACEIs) are commonly used to treat hypertension. Although generally well tolerated, the adverse effects of ACEIs include hypotension, cough, acute kidney injury and hyperkalemia. Rare reports of ACEI-induced hepatotoxicity have been described, most notab...
Autores principales: | Forner, David, Kulai, Tasha, Arnason, Thomas, E. Gruchy, Steven, MacLeod, Magnus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495903/ https://www.ncbi.nlm.nih.gov/pubmed/28702139 |
Ejemplares similares
-
Duodenal Villous Atrophy in a TTG-Negative Patient Taking Olmesartan: A Case Report and Review of the Literature
por: Kulai, Tasha, et al.
Publicado: (2016) -
Ramipril: Aggravation of liver toxicity: case report
Publicado: (2020) -
Assessment of cholestasis in drug-induced liver injury by different methods
por: Xing, Mindan, et al.
Publicado: (2019) -
Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence
por: Simonyi, Gábor, et al.
Publicado: (2016) -
Cholestasis in Benign Recurrent Intrahepatic Cholestasis 2
por: Arthur Lorio, Eric, et al.
Publicado: (2020)